Asset Turnover is linked to ROE % through Du Pont Formula. Naturewise Biotech & Medicals's annualizedROE % for the quarter that ended in Dec. 2025 was -19.38%. It is also linked to ROA % through Du Pont Formula. Naturewise Biotech & Medicals's annualizedROA % for the quarter that ended in Dec. 2025 was -16.91%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Naturewise Biotech & Medicals's annulizedROA % for the quarter that ended in Dec. 2025 is
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Naturewise Biotech & Medicals Asset Turnover Related Terms
Naturewise Biotech & Medicals Asset Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4732 vs VRTX, REGN, ALNY: Asset Turnover Comparison
For the Biotechnology subindustry, Naturewise Biotech & Medicals's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturewise Biotech & Medicals Asset Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Naturewise Biotech & Medicals's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Naturewise Biotech & Medicals (ROCO:4732) has a Asset Turnover of 0.12 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Naturewise Biotech & Medicals and its competitors.
Is Naturewise Biotech & Medicals' Asset Turnover too high?
Naturewise Biotech & Medicals' current Asset Turnover is 0.12. Overall, Naturewise Biotech & Medicals has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Asset Turnover compare to VRTX and REGN?
Naturewise Biotech & Medicals' Asset Turnover of 0.12 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Asset Turnover is 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.11, compared to a current price of NT$17.00 — trading 23.1% below its estimated fair value. The current Asset Turnover is 0.12. Naturewise Biotech & Medicals' overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Asset Turnover is 0.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued.
The current stock price of NT$17.00 is trading 23.1% below its estimated GF Value™ of NT$22.11.
GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.
Key valuation signals for ROCO:4732:
Asset Turnover: 0.12
GF Value™: NT$22.11 vs. price of NT$17.00 (23.1% below fair value)
No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturewise Biotech & Medicals Business Description
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
62GF Score
Get the complete analysis for ROCO:4732
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4732 has been successfully added to your 
